Related Experiment Video
Updated: Aug 1, 2026
10:27
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Etanercept for psoriasis: two case reports
A Fidalgo1, J Baptista, F Rocha Páris
1Dermatology Department, Desterro Hospital, Lisbon, Portugal. ana.fidalgo@netcabo.pt
International Journal of Clinical Pharmacology Research
|January 13, 2006
Summary
Etanercept, a biologic targeting tumor necrosis factor-alpha (TNF-alpha), effectively treated severe psoriasis and psoriatic arthritis in two cases. This TNF antagonism approach showed remarkable improvement with no adverse events.
Area of Science:
- Immunodermatology
- Rheumatology
- Pharmacology
Background:
- Psoriasis is a chronic T-cell mediated inflammatory skin disease.
- Tumor necrosis factor-alpha (TNF-alpha) plays a key role in psoriasis pathogenesis.
- Biological agents offer targeted therapies for conventional systemic medication alternatives.
Observation:
- Two patients with severe, recalcitrant psoriasis and psoriatic arthritis were treated.
- Etanercept, a TNF-alpha inhibitor, was administered to the patients.
- Treatment outcomes were monitored for efficacy and adverse events.
Findings:
- Both patients experienced remarkable improvement in their severe psoriasis and arthritis.
- Etanercept demonstrated significant efficacy in managing treatment-resistant cases.
- No adverse events were reported during the treatment period.
Implications:
- TNF antagonism with etanercept is a promising therapeutic strategy for severe psoriasis and psoriatic arthritis.
- This approach offers an effective alternative for patients unresponsive to traditional treatments.
- Further research into etanercept's long-term efficacy and safety in psoriasis is warranted.
